



Meredith M Regan

Contact

Meredith M Regan

Publications (38)

Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown L, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller-Hübenthal B, Jochum W, Bonnefoi H, Martino S, Davidson N, Geyer C, Chia S, Ingle J, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates A, Goldhirsch A, Fleming G, Francis P, Speed T, Regan M, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. *Ann Oncol* 2023; 34:397-409.

Leone J, Vaz-Luis I, Colleoni M, Di Leo A, Goldhirsch A, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Gelber R, Giobbie-Hurder A, Rabaglio M, Coates A, Thürlimann B, Regan M, Cole B, Lin N. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. *Cancer* 2020

Rabaglio M, Thürlimann B, Colleoni M, Goldhirsch A, Gelber R, Coates A, Castiglione M, Ruepp B, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Giobbie-Hurder A, Maibach R, Sun Z, Regan M. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. *Breast Cancer Res Treat* 2020

Buechler S, Badve S, Leyland-Jones B, Viale G, Kammler R, Thürlimann B, Willis S, Gökmen-Polar Y, Gray K, Regan M. Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. *JNCI Cancer Spectr* 2019; 3:pkz051.

Denkert C, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B, Dietel M, Fasching P, Colleoni M, Blohmer J, Mehta K, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Solbach C, Thürlimann B, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. *Breast Cancer Res Treat* 2019; 176:557-568.

Kensler K, Brown M, Viale G, Colleoni M, Thürlimann B, Kammler R, Hazra A, Schnitt S, Pyle M, Baker G, Heng Y, Regan M, Tamimi R. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. *Breast Cancer Res* 2019; 21:30.

Ruhstaller T, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R, Coates A, Goldhirsch A, Thürlimann B, Regan M, Veyret C, Del Mastro L, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen E, Gladieff L, Bonnefoi H, Harvey V, Spazzapan S, Tondini C, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. *J Clin Oncol* 2018;JCO1800440.

Galimberti V, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan M, Coates A, Gelber R, Goldhirsch A, Littlejohn D, Taffurelli M, Cole B, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol* 2018

Van Asten K, Van Calster B, Christodoulou E, Vergote I, Thürlimann B, Viale G, Regan M, Giobbie-Hurder A, Paridaens R, Smeets A, Weltens C, Van Limbergen E, Floris G, Wildiers H, Brouckaert O, Jongen L, Olbrecht S, Slembrouck L, Neven P. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. *Oncologist* 2018

Luen S, Regan M, Colleoni M, Viale G, Thürlimann B, Hackl W, Dolan S, JeBailey L, Demanse D, Biasi O, Dell'Orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. *JAMA Oncol* 2018

Francis P, Pavesi L, Ruhstaller T, Davidson N, Coleman R, Debled M, Buchholz S, Ingle J, Winer E, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates A, Gelber R, Goldhirsch A, Regan M, Climent M, Spazzapan S, Puglisi F, Pagani O, Fleming G, Walley B, Colleoni M, Láng I, Gomez H, Tondini C, Ciruelos E, Burstein H, Bonnefoi H, Bellet M, Martino S, Geyer C, Goetz M, Stearns V, Pinotti G, SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med* 2018; 379:122-137.

Dowsett M, Sestak I, Regan M, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. *J Clin Oncol* 2018; 36:1941-1948.

Munzone E, Barberis M, Goldhirsch A, Regan M, Gelber R, Coates A, Di Leo A, Viale G, Kammler R, Gianni L, Ruhstaller T, Láng I, Guerini-Rocco E, Fumagalli C, Gray K, Colleoni M. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. *Breast Cancer Res Treat* 2018; 170:351-360.

Wapnir I, Gelber S, Coates A, Gelber R, Rastogi P, Regan M, Wolmark N, Aebi S, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer C, Mamounas E, Thürlimann B, Price K, Anderson S, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, Láng I, Baena-Cañada J, Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. *J Clin Oncol* 2018; 36:1073-1079.

Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017; 19:127-138.

Bartlett J, Rea D, Dowsett M, Cuzick J, Viale G, Forbes J, Brookes C, Van de Velde C, Putter H, Seynaeve C, Thürlimann B, Dell'Orto P, Mallon E, Sestak I, Regan M, Ahmed I. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. *Eur J Cancer* 2017; 79:129-138.

Borgquist S, Regan M, Gelber R, Price K, Rabaglio M, Goldhirsch A, Coates A, Smith I, von Moos R, Ejlertsen B, Debled M, Láng I, Colleoni M, Garber J, Ahern T, Giobbie-Hurder A, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. *J Clin Oncol* 2017; 35:1179-1188.

Pruneri G, Regan M, Gelber R, Munzone E, Cancellato G, Price K, Kammler R, Goldhirsch A, Gianni L, Ruhstaller T, Láng I, Criscitiello C, Curigliano G, Viale G, Vingiani A, Gray K, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat* 2016; 158:323-31.

Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. *J Clin Oncol* 2016

Ribi K, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Neven P, Perelló A, Kerbrat P, Luo W, Bernhard J, Francis P, Burstein H, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Fleming G. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. *J Clin Oncol* 2016; 34:1601-10.

Leyland-Jones B, Maibach R, Price K, Coates A, Goldhirsch A, Gelber R, Pagani O, Viale G, Rae J, Regan M, Arnould L, Neven P, Harvey V, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, BIG 1-98 Collaborative Group. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. *Breast Cancer Res Treat* 2015; 154:543-55.

Regan M, Sessa F, Peg Cámara V, Rodríguez Peralto J, MacGrogan G, Colleoni M, Goldhirsch A, Price K, Coates A, Gelber R, Viale G, Öhlschlegel C, Pizzolitto S, Pagani O, Francis P, Fleming G, Walley B, Kammler R, Dell'Orto P, Russo L, Szóke J, Doimi F, Villani L, SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Res Treat* 2015

Metzger Filho O, Coates A, Regan M, Price K, Debled M, Ejlersen B, Colleoni M, Gelber R, Thürlimann B, Winer E, Viale G, Gusterson B, Mallon E, Giobbie-Hurder A, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. *J Clin Oncol* 2015; 33:2772-9.

Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. *Lancet Oncol* 2015; 16:848-58.

Leyland-Jones B, Neven P, Treilleux I, Rasmussen B, Maibach R, Price K, Coates A, Goldhirsch A, Pagani O, Viale G, Rae J, Harvey V, Ditzel H, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Lyng M, Regan M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. *Breast Cancer Res Treat* 2015; 151:373-84.

Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2014; 371:107-18.

Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlersen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. *J Clin Oncol* 2012; 30:3967-75.

Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. *J Natl Cancer Inst* 2012; 104:441-51.

Regan M, BIG 1-98 Collaborative Group, Thürlimann B, Coates A, Gelber R, Price K, Rabaglio M, Wardley A, Láng I, Smith I, Forbes J, Mauriac L, Ejlersen B, Goldhirsch A, Giobbie-Hurder A, Neven P, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncol* 2011; 12:1101-8.

Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Res Treat* 2011; 131:295-306.

Regan M, Price K, Giobbie-Hurder A, Thürlimann B, Gelber R, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. *Breast Cancer Res* 2011; 13:209.

Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. *J Clin Oncol* 2011; 29:1117-24.

BIG 1-98 Collaborative Group, Gelber R, Regan M, Price K, Forbes J, Mauriac L, Smith I, Paridaens R, Thürlimann B, Goldhirsch A, Giobbie-Hurder A, Mouridsen H, Coates A. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *NEJM* 2009; 361:766-76.

Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Braye S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. *J Clin Oncol* 2008; 26:5569-75.

Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Rusca T, Grigolato P, Braye S, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Mastropasqua M, Maiorano E, Regan M, Coates A. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. *J Clin Oncol* 2008; 26:1404-10.

Viale G, Coates A, Goldhirsch A, Gelber R, Castiglione-Gertsch M, Gusterson B, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Price K, Colleoni M, Maiorano E, Maffini F, Mastropasqua M, Regan M, International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. *J Natl Cancer Inst* 2008; 100:207-12.

Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. *The Lancet* 2008; 9:23-8.

Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. *J Clin Oncol* 2007; 25:3846-52.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch